The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
The Ma’anshan site approval covers pastilles, oral liquids, and powders
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Subscribe To Our Newsletter & Stay Updated
